PURE Bioscience reported fiscal 2026 net product sales of $2.315 million, versus $2.198 million in fiscal 2025; the $117,000 increase was attributed to higher sales across its end-user network serving food processing. Gross margin was 57%, compared with 59%; selling, general and administrative expense was $3.077 million versus $3.259 million, and research and development expense was $332,000 versus $316,000. The company recorded a $2.483 million net loss and used $1.738 million of cash in operating activities in fiscal 2026.
At July 31, 2026, cash and cash equivalents were $569,000 compared with $334,000 as of July 31, 2025; total liabilities were $7.592 million, and stockholders’ deficiency was $6.399 million. As of July 31, 2026, convertible notes payable of $1.015 million were past due. PURE said these conditions raise substantial doubt about its ability to continue as a going concern within one year after the report date. On February 13, 2026, it issued convertible notes with an aggregate principal balance of $970,000 under its fiscal 2026 note purchase agreement.
PURE Bioscience reported total revenue of $2.318 million for the fiscal year ended July 31, 2026, compared with $2.202 million in fiscal 2025. Net product sales were $2.315 million, an increase of $117,000; gross profit was $1.326 million versus $1.303 million. Net loss was ($2.483 million) compared with ($2.399 million), and net cash used in operations was ($1.97 million) versus ($2.0 million). Net loss excluding share-based compensation was ($2.3 million) in both years.
Cash and cash equivalents were $569,000 at July 31, 2026, compared with $334,000 a year earlier. Current related-party convertible notes payable totaled $3.381 million, including $1.015 million past due; total current liabilities were $4.371 million. Stockholders’ deficiency was $6.399 million.
PURE Bioscience, Inc. completed a $555,000 private placement on October 15, 2026, issuing 10,183,486 common shares at $0.0545 per share to accredited investors. Board member Tom Y. Lee invested $555,000 directly and through his affiliates; the disinterested directors approved the financing. The shares were issued under a Securities Purchase Agreement.
Net proceeds, after fees and other offering expenses, are expected to be approximately $555,000. PURE expects to use them for general corporate purposes, including research and development, general administrative expenses and working capital. The unregistered issuance relied on an exemption under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. Investors represented that they were accredited investors purchasing for their own accounts and without a view to distribution.
PURE Bioscience, Inc. reports continued losses but modest revenue growth for the three and nine months ended April 30, 2026. Net product sales reached $506,000 for the quarter and $1,656,000 year-to-date, up from $489,000 and $1,435,000 in 2025. Net loss was $624,000 for the quarter and $1,873,000 for nine months, similar to the prior year, as operating expenses remained higher than gross profit.
The company highlights substantial doubt about its ability to continue as a going concern, with a stockholders’ deficiency of $5,839,000 and total convertible notes and accrued interest of $6,497,000. To support liquidity, PURE raised about $1.0 million through a private placement of 18,131,096 common shares at $0.0553 per share and issued $970,000 of new related-party convertible notes. Cash and cash equivalents improved to $983,000, but operations used $1,324,000 of cash over nine months.
The company increased authorized common shares from 200 million to 250 million, with 130,017,569 shares outstanding as of June 15, 2026, and notes that its debt is currently convertible into 57,763,172 shares. PURE also announced a leadership transition: CEO Robert Bartlett will retire effective August 1, 2026, with President Jeffrey Kitchell becoming Chief Executive Officer and joining the Board.
PURE Bioscience reported modestly higher sales but continuing losses for its fiscal third quarter ended April 30, 2026. Net product sales were $506,000, up slightly from $489,000 a year earlier, while net loss widened to $624,000 from $580,000, with loss per share steady at ($0.01).
For the first nine months of fiscal 2026, net product sales rose to $1,656,000 from $1,435,000, and net loss improved to $1,873,000 from $2,067,000. At April 30, 2026, cash and cash equivalents were $983,000 and total liabilities were $7,397,000, including significant convertible notes to related parties, resulting in a stockholders’ deficiency of $5,839,000.
The company highlighted growing adoption of products such as PURE® Clean and its transportation and dairy programs, supported by distribution partners. PURE also announced a leadership transition: CEO Robert Bartlett plans to retire effective July 31, 2026, remaining on the board and as advisor, while President Jeff Kitchell will become CEO and a director on August 1, 2026. Director Bernard Blotner will leave the board to focus on his health.
PURE Bioscience, Inc. entered into a private placement financing on April 30, 2026, raising $1.0 million by issuing 18,131,096 shares of common stock at $0.0553 per share to accredited investors. Board members Tom Y. Lee and Ivan Chen invested approximately $700,000 and $27,650, respectively, with disinterested directors approving the transaction.
The company expects net proceeds of about $1.0 million, which it plans to use for general corporate purposes, including research and development, administrative expenses, and working capital. The unregistered offering relied on exemptions under Section 4(a)(2) and Rule 506 of Regulation D, with investors representing accredited status.
PURE Bioscience, Inc. reported higher sales but continued losses for the three and six months ended January 31, 2026, while warning about its ability to continue as a going concern. Net product sales rose to $443,000 for the quarter and $1,150,000 for the six-month period, reflecting broader demand across its end‑user network.
Despite a six‑month gross margin of 60%, PURE posted a six‑month net loss of $1,249,000, narrowing from $1,487,000 a year earlier, and a quarterly net loss of $785,000. Operating cash outflows were $856,000 for six months, leaving only $198,000 in cash and $273,000 including restricted cash.
PURE’s balance sheet remains highly leveraged and negative. As of January 31, 2026, stockholders’ deficiency was $6,273,000, total assets were $788,000, and total liabilities were $7,061,000, including $6,145,000 of convertible notes and accrued interest owed to related parties. Management and the auditor both cite substantial doubt about the company’s ability to continue as a going concern without new financing.
PURE Bioscience, Inc. reported fiscal second quarter 2026 results, showing modest growth with continued losses. Net product sales for the quarter rose to $443,000 from $391,000 a year earlier, while net loss was roughly flat at $785,000 versus $798,000.
For the six months ended January 31, 2026, net product sales increased to $1,150,000 from $946,000, and net loss improved to $1,249,000 from $1,487,000, helped by lower selling, general and administrative costs. Net loss per share remained at $(0.01) for both periods.
The balance sheet shows limited liquidity, with cash and cash equivalents of $198,000 and restricted cash of $75,000 at January 31, 2026, against total liabilities of $7,061,000 and a stockholders’ deficiency of $6,273,000. Common shares issued and outstanding were 111,886,473.
Operationally, PURE obtained USDA Biobased Product Certification for its new product PURE Clean and expects to launch it and fulfill pre-orders in the fiscal third quarter. The company is expanding applications in dairy plants, transportation, and exploring biomedical opportunities through partners, aiming to grow recurring revenue from its SDC-based antimicrobial technology.
Pure Bioscience, Inc. reported the results of its annual stockholder meeting held on February 17, 2026. Shareholders representing 65.97% of the 111,886,485 outstanding common shares were present in person or by proxy.
All seven director nominees were elected, each receiving more than 96% of votes cast. Stockholders also ratified Weinberg & Company, P.A. as independent auditor for the fiscal year ending July 31, 2026, with 99.81% of votes cast in favor.
On an advisory basis, stockholders approved executive compensation with 96.68% of votes cast in favor. They also approved an amendment to the Certificate of Incorporation to increase authorized common stock from 200,000,000 to 250,000,000 shares, supported by 63.87% of outstanding common shares.
PURE Bioscience, Inc. has called its 2026 annual stockholder meeting for February 17, 2026 at 10:30 a.m. local time in Huntington Beach, California. Stockholders of record as of December 22, 2025, when 111,886,485 shares of common stock were outstanding, will vote on four key items.
They are being asked to elect seven directors, ratify Weinberg & Company, P.A. as independent auditor for the fiscal year ending July 31, 2026, approve on an advisory basis the compensation of named executive officers, and approve an amendment to the Certificate of Incorporation to increase authorized common shares from 200,000,000 to 250,000,000. As of December 22, 2025, a total of 176,722,446 shares were outstanding or reserved under options, RSUs, convertible debt and the 2024 Equity Incentive Plan, so the additional authorization is intended to provide flexibility for future financings, equity compensation and other corporate purposes. The Board recommends voting in favor of all proposals.